Objective: To observe the effectiveness of Xueshuantong combined with prostaglandin E1 in treatment of peripheral arterial disease and its effect on blood rheology. Method: The 91 patients with peripheral arterial disease from July 2013 to June 2014 were divided into two groups according to random number. Patients in treatment group(46 cases) were treated with Xueshuantong combined with prostaglandin E1

while patients in control group (45 cases) were treated with prostaglandin E1.After treatment

the curative effect of two groups was observed;ankle brachial index(ABI)

toe brachial index (TBI)

dorsalis pedis artery blood flow

and hemodynamic indexes were observed before and after treatment in both groups. Result: There was no statistically significant difference between two groups in general data such as patients age

sex

fortain stage

body mass index

pathological changes of lower limbs

ABI

TBI

the dorsalis pedis artery blood flow

tumor necrosis factor-alpha (TNF-α)

interleukin-6 (IL-6)

hypersensitive C-reactive protein (hs-CRP) and hemodynamic indexes. After treatment

total effective rate was 95.65% in treatment group

higher than 82.61% in control group

with significant difference (P<0.05). After treatment

ABI

TBI

dorsalis pedis artery blood flow were significantly higher than those before treatment in both groups

with significant difference (P<0.05)

and the above levels in treatment group were significantly higher than those in control group after treatment (P<0.05). After treatment

hemodynamic indexes of two groups were reduced significantly (P<0.05)

and the reduction degree in treatment group was significantly greater than that in control group (P<0.05). In the process of treatment

liver or kidney functional abnormities were present in both groups

but they turned back to normal levels after symptomatic treatment

with no difference in incidence of adverse reactions between two groups. Conclusion: Xueshuantong combined with prostaglandin E1 has good effect in treatment of peripheral arterial disease

which could improve the clinical symptoms and hemodynamics

and inhibit the inflammatory response.